A28 Therapeutics

A28 Therapeutics is a privately-held, clinical-stage biopharmaceutical company founded in 2021, focused on developing its targeted oncolytic peptide platform for the treatment of multiple cancer types. Its lead compound, AT-101, has been clinically tested through a Phase 2a study and is being developed for indications including metastatic ovarian cancer with liver metastases and hepatocellular carcinoma.

A28 Therapeutics was founded in 2021 by Stanley Lewis, who serves as CEO. The company is a privately-held, clinical-stage biopharmaceutical company focused on developing its targeted oncolytic peptide platform for treating multiple cancer types. Its lead compound, AT-101, has been clinically tested through a Phase 2a study.

1. A28 Therapeutics: Targeted Oncolytic Peptides (TOPs) for treating Cancer
2. About : A28 Therapeutics
3. A28 Therapeutics